GSK’s RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk

GSK’s RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk  GSK US


2 h.
Science
ID: 1099693462055941027


Similar News expand_more


Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Science
Crime
Science
Science
Science
Science
Science
Military
Travel
Science
Entertainment
Science
Technology
Science
Science
Science
Science
Popular countries based on strong economic and political relations

Add Watch Country

arrow_drop_down